The team of scientists who made a ground-breaking gene discovery which transformed the field of cancer research have been celebrated with the unveiling of two commemorative plaques in London today. The plaques pay homage to the 41 scientists who made the landmark discovery of the BRCA2 cancer gene at the ICR in 1995.

The Institute of Cancer Research, London, is urging NHS-England, NICE and pharmaceutical company AstraZeneca to continue discussions after the disappointing decision not to recommend targeted drug olaparib for women with early-stage, high-risk, inherited breast cancer.

The Institute of Cancer Research, London, celebrates the news that the precision medicine olaparib has been approved by the UK regulator, the Medicines and Healthcare products Regulatory Agency (MHRA), for patients with high-risk, early-stage breast cancer and inherited faults in their BRCA1 or BRCA2 genes.